All Oncology News

OS Therapies submits a RMAT designation request for OST-HER2 for the treatment of patients with pediatric lung-metastatic osteosarcoma.

The FDA has lifted the partial clinical hold on a phase 3 study assessing IFx-2.0 in advanced Merkel cell carcinoma.

Daneng Li, MD, discusses the IL-27–targeted agent casdozokitug in hepatocellular carcinoma.

Erica L. Mayer, MD, MPH, discusses the implications of data from the SERENA-6 trial for ESR1 testing in hormone receptor–positive breast cancer.

Suresh S. Ramalingam, MD, FACP, FASCO, highlights his journey in the lung cancer field, leading up to his recognition on the TIME100 Health 2025 list.

The top oncology videos of the week for the week of June 1, 2025, including updates from the 2025 ASCO Annual Meeting.

RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.

Revisit key updates from the ASCO Annual Meeting, the FDA, NCCN, and more.

The photosensitizing drug and light delivery system yielded complete responses and a low rate of disease recurrence in patients with low-grade UTUC.

Perioperative sacituzumab govitecan-hziy plus pembrolizumab was safe and active in muscle-invasive bladder cancer.

Tess O’Meara, MD, discusses the implications of data from the DESTINY-Breast09 trial of first-line T-DXd plus pertuzumab in HER2-positive breast cancer.

Elizabeth Mittendorf, MD, PhD, MHCM, discusses advancing ASCO’s mission through research advocacy, global collaboration, and a commitment to equity.

Time-limited therapy with acalabrutinib plus venetoclax with or without obinutuzumab is approved in the European Union for untreated patients with CLL.

The FDA received an NDA for vepdegestrant in ER-positive, HER2-negative advanced breast cancer with an ESR1 mutation.

Nitin Jain, MD, discusses the role pirtobrutinib has played in the chronic lymphocytic leukemia treatment paradigm.

Experts highlight key abstracts to watch for at the 2025 EHA Congress.

RP1/nivolumab generated responses in deep/visceral lesions and in non-injected lesions in advanced PD-1–refractory melanoma.

Kanwarpal S. Kahlon, MD, discusses the implications of the availability of generic eltrombopag for immune thrombocytopenia and severe aplastic anemia.

Vivek Patel, MD, discusses the growing body of data supporting the use of bispecific antibodies in patients with relapsed/refractory follicular lymphoma.

A protein called PCSK9 determines how pancreatic cancer cells metastasize to different parts of the body.

Epcoritamab monotherapy yielded durable remissions and survival benefits in relapsed/refractory LBCL that remained in CR 2 years after starting treatment.

Cadonilimab plus chemotherapy with or without bevacizumab has received NMPA approval for first-line recurrent or metastatic cervical cancer.

A new drug application seeking the Chinese approval of sintilimab plus fruquintinib in second-line advanced/metastatic RCC has been accepted by the NMPA

The evaluation of diverse biomarkers via a machine learning approach demonstrated improved prediction of clinical outcomes vs individual biomarkers in RCC.

Daneng Li, MD, discusses the efficacy and safety findings of a casdozokitug-based regimen in unresectable, advanced HCC.

IMA203 was well tolerated and elicited durable responses in patients with advanced melanoma.

Elizabeth Mittendorf, MD, PhD, shares her ASCO priorities: expanding trial access, strengthening teams, and advancing global, evidence-based oncology care.

JNJ-79635322 had a tolerable safety profile and elicited responses comparable with those generated by CAR T-cell therapy in relapsed/refractory myeloma.

Tivozanib monotherapy was effective and outperformed tivozanib plus nivolumab after receipt of upfront IO/TKI or ipilimumab/nivolumab regimens in RCC.